Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
At this point I believe the FDA IDE study is now more for Davita interest. If They can produce great study outcomes this is a revenue avenue that Davita will never let go of, especially now since Davita has made it known that they are headed into Hep and HIV testing with Roche's high tech testing device. Davita is testing the waters with the IDE test, and have larger plans with success. IMO. If all goes well Aethlon will have easier days ahead.
Well, lets hope they now have money for extra advertizing. 8,000 seems a little extreme for a stock at .18+
I agree. IMO it looks like Aethlon is just loading up information to shareholders and stalling until the agreements are set.
Lets also not forget that JJ mentioned during a presentation that they were working with two larger companies with the global infrastructure to complete their entire goal (Something like that)
https://finance.yahoo.com/news/davita-labs-uses-roche-technology-100300935.html
Looks like Davita is setting the stage...Umm
Based on my prior post, and again I'm assuming, I believe that the partnership PR was announced at about the same time the trials were completed. The details of the partnership will be announced once the FDA approves. Again, my belief is based on Davita only partnering knowing that the IDE trials had good results. IMO we are only waiting now for the FDA. This is also why we have had no updates and Aethlon has not updated their website. It's an FDA waiting game...Any other opinions?
Well there's not much else to do but speculate. Someone mentioned in a past post about the FDA IDE already being in the works. I'm also thinking that the Trial is up and running.
JJ mentioned that they started discussions with Davita soon after they received FDA approval last year. With that said they have had about a half a year of discussions prior to any announcement of a partnership. It wasn't until last month that they announced an upcoming partnership with Davita. I would assume that Davita would not fully partner until they were completely confident with the FDA IDE results. With that said, I believe the trials have been started, probably several months ago and we are waiting for both the results and finalization of the partnership if all goes well.IMO... Any thoughts?
My guess is that Aethlon is holding off on their new website until they finalize one more partnership, probably with a drug company. In order to have a global infrastructure to complete the entire regulatory plan [Per JJ] Aethlon would have to have a drug company on board. With two large companies (Davita and a drug company) Aethlon would be set up perfectly for IDE studies and beyond. This is worth the wait...IMO.
For now anyway, but next week will be another bump upward. JJ will not wait too long now to provide PR on the FDA IDE start up and upload Aethlon's new website, since currently the websites totally contradict each other. I think JJ has a good plan and we should see good PR's once a week until the end of the month. IMO
This week was ESI's time with the great news and website start up. I'm sure the same company worked on both websites, so my guess is next week is Aethlon's moment with FDA IDE info and start up date with Aethlon's new website. IMO they can't be too far apart.
Davita is a great partner, but I'm holding JJ at his word that there is one more. He mentioned they were in discussions with two larger companies, so hopefully the next one will come soon, since they were announced at the same time.
They may have the device, but Aethlon currently holds the patent
There have been no updates from Aethlon, regarding Hep C/Hemopurifier, since their announcement of the FDA IDE approval, which was about eight months ago. So, within the last eight months all we know is that they're in discussions with two larger companies, and we found that out in JJ's last presentation. Whatever is going on sure is taking awhile. Makes me wonder what the discussions are really about. I don't believe they will start the IDE study without an announcement, so it looks like we have a few more months. I do believe that once they announce the two larger companies the wait will be worth it.
http://www.nzherald.co.nz/health/news/article.cfm?c_id=204&objectid=11197101
Kiwis cover new ground in cancer fight
11:30 AM Wednesday Feb 5, 2014
New Zealand scientists have edged closer to new therapies to enhance the body's immune response to cancer.
Otago University researchers have uncovered a pathway that alters the immune response in the spleen and lymph system when faced with cancerous tumour cells.
The research, just published in American haematology journal Blood, has identified the pathway, or mechanism used when cells remove unwanted material in lipid-bound particles called exosomes.
Exosomes are only 1/10,000 of a millimetre in diameter but are important in immunity as they contain proteins that can enhance or suppress the immune response against cancer and have recently been exploited as cancer vaccines.
They have also been implicated in autoimmune diseases.
Lead researcher Associate Professor Alex McLellan, from Otago's Department of Microbiology and Immunology, said although the existence of exosomes had been known since the early 1970s, the fate of the released exosomes in the lymph system or blood was poorly understood until now.
"We have discovered how exosomes are removed from circulation or lymph fluid and taken up by the immune system, and how this uptake system suppresses the immune response to these circulating particles," he said.
"In a normally functioning body this works in our favour to prevent autoimmunity, but when cancerous cells are involved you want to block this pathway to make the immune system more aggressive.
"Although exosomes are normally removed from circulation within minutes, we were able to induce strong immune responses to the exosomes by blocking this uptake system."
The study also was the first to record a circulation half life for exosomes.
Associate Professor McLellan, doctoral student Sarah Saunderson and colleagues found that the newly discovered mechanism uses a receptor called CD169 or sialoadhesin that was expressed on the lymph node or spleen that recognised sugars (sialic acids) present on the surface of the exosomes.
In the absence of this uptake mechanism, immune responses were significantly enhanced in the spleen and lymph nodes.
"This suggests that when vesicle-uptake is working normally, inappropriate immune responses against self-tissues are prevented," Associate Professor McLellan said.
"Since tumours are also self-tissue the next application is to design small molecule inhibitors to block this pathway to enhance the body's immune response to cancer.
"The work has identified a new pathway of intercellular communication, a process that has involved seven years of work in the laboratory, and that has the potential to inform clinical developments in the fields of autoimmunity and tumour immunotherapy.
"This is relevant to all types of cancer that can be recognised by the immune system, including melanoma, and also autoimmune disorders."
The study was conducted with assistance from the Marsden Fund and also University of Otago grants.
What I find concerning is during JJ's last presentation he said they were in discussions with two larger companies. He did not say partnership discussions with two larger companies, which would have made it obvious. Plus how long do discussions take?
Below was taken from the June 25th 2013 PR.
"Aethlon Medical has been laying the groundwork necessary to implement the now approved clinical trial protocol for several years" said Rod Kenley, Aethlon's President. "We are finally able to move forward with our contract research and clinical partners in finalizing all of the activities that can now take place prior to initiating treatment of the first patient. While there is still some work to be done, today the biggest hurdle has been cleared and we are anxious to make rapid progress towards commercialization."
I may be wrong but this delay does not seem like Rapid progress. The question I have is why did Aethlon move to dealing with another two larger companies when everything was already set? Also, is this move a partnering discussion or maybe a acquisition discussion?
As we know, Aethlon announced FDA IDE approval on June 25th 2013. Seven months later (Jan. 14th) JJ announces changes and discussions with two larger companies for the FDA IDE studies. Now we are entering our eighth month and still no idea of when they plan the start up. Below was taken from the FDA approval PR.
"Aethlon Medical has been laying the groundwork necessary to implement the now approved clinical trial protocol for several years" said Rod Kenley, Aethlon's President. "We are finally able to move forward with our contract research and clinical partners in finalizing all of the activities that can now take place prior to initiating treatment of the first patient. While there is still some work to be done, today the biggest hurdle has been cleared and we are anxious to make rapid progress towards commercialization."
Well IMO, if eight months is anxious rapid progress with no updates, then who knows when this will happen. A shareholders letter would have been nice, just to keep us a little informed. All this secret squirrel stuff, better be worth this long unknown wait. Thanks for letting me vent. I feel a little better now.
Isn't anyone else confused about these articles. We have known that Aethlon can detect different types of cancer exosomes using their EllSA test for over a year, so why is MD Anderson getting the PR credit for a simple blood tests for cancer exosomes? It's not new news, just a larger company. IMO, there is no way MD Anderson is allowing this unless they have connections with Aethlon. Maybe they are using Aethlon's ELLSA test for their research. How do you think Aethlon found different types of cancer exosomes, but by sampling blood, but yet the PR is flying off of just one MD Anderson PR. Please educate me on this issue.
It's coming. JJ said at his last presentation that they are in partnership discussions with two larger companies. They can't talk forever, so I believe it's coming really soon and this partnership will put us on the map. As I said in a previous post I don't think it's a mystery why MD Anderson is now in articles involving exosomes. It's also interesting that a couple of weeks ago MD Anderson announced a partnership, but also said another partnership was coming really soon, but it has not been announced. I may be completely wrong, but in my opinion the puzzle pieces are too close to a match. Either way, we should find out soon who they are and it's good news either way.
This is what happens when your bored. I listened to JJ's last presentation again and found his presentation structure interesting.
JJ's first 6 minutes, or so, and last 4 minutes discussed exosomes. JJ said the word "Exosome" 23 times and "Hep C" only approx. 4 times. The discussion of Hep C was structured well into the second half of his presentation. It's interesting to me that he opened and closed his presentation with exosomes. Some may say, "So what," but it shows to me what he feels is more important, or exciting at this time.
What I also heard was "strategy" and "progression". He talked about Aethlon's entire regulatory plan being accomplished by two new larger companies that have the global infrastructure to accomplish the plan.
What I gather is these two larger companies have the ability to help and complete every avenue Aethlon has in mind, which is a lot.
So, I'm looking forward to finding out when the FDA IDE study will take place and the announcement of the two new larger companies. This announcement could be a game changer.
This is just my opinion on JJ's presentation. It seemed to me that Aethlon is now placing a lot of weight on exosomes. JJ discussed more about other uses and avenues for the hemopurifier then Hep C alone. He talks about two new larger companies now in the works for the FDA IDE? I'm guessing that the other two (Larger)companies are associated to cancer and exosomes. I feel that JJ sees more revenue with cancer and exosomes and Hep C is now running third. This may be wishful thinking, but MD Anderson and Pfizer just joined as partners in the Moon Shot Program. About 75% of JJ presentation is about cancer and exosomes. JJ announced a change in the FDA IDE study to two larger companies. Yes, I'm still stuck on MD Anderson being associated with Aethlon and ESI. Lets hope we find out soon.
I have a question that I believe we have discussed before. Now that research has pretty much proven that exosomes have the same DNA as their host cell and that tumor secreted exosomes are a possible cause of metastasis then shouldn't there be a worry about blood transfusions?
lets say that a person gives blood and has no idea that they have a cancerous tumor. Could one persons tumor secreted exosome effect another?
With that possibility then eventually they will need to screen/filter all blood banks for possible tumor secreted exosomes before it could be used. Or test an individual before giving blood. I would say if this is possible then there is a definite need for the Hemopurifier.
"Blood transfusions are very common. Each year, almost 5 million Americans need a blood transfusion. Most blood transfusions go well. Mild complications can occur. Very rarely, serious problems develop." http://www.nhlbi.nih.gov/health/health-topics/topics/bt/
Here is a pep talk from one of our long term investors. Go Team!
Aethlon's patent,
US8288172 Mar 9, 2007 Oct 16, 2012 Aethlon Medical, Inc. Extracorporeal removal of microvesicular particles
, covers the use of a filter device to collect exosomes. There is another patent listed below which allows for testing of microvesicles. I believe the below patent is what MD Anderson is working off of.
WO2009100029A1 * Feb 2, 2009 Aug 13, 2009 Gen Hospital Corp Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
Again, I'm not sure. If anyone has more info please assist
http://www.xconomy.com/texas/2014/01/08/houstons-md-anderson-partners-with-pfizer-on-cancer-immunotherapies/
Houston’s MD Anderson Partners With Pfizer on Cancer Immunotherapies
Angela Shah1/8/14Follow @angelashah
Moon Shots
Share and Comment
Leave a Comment Order a Reprint E-mail this Story
1
inShare
The University of Texas MD Anderson Cancer Center has a new partnership with Pfizer (Nasdaq: PFE) that moves forward a key component of the hospital’s year-old “Moon Shots” program aimed at dramatically improving survival of cancer patients.
The hospital announced Monday it will work with the New York City-based pharmaceutical giant to develop immunotherapies, an approach that stimulates the patient’s own immune system to fight cancer. At the helm will be Jim Allison, renowned for the development of an immunotherapy drug that targets melanoma, and who, in 2012, was recruited away from Memorial Sloan-Kettering Cancer Center in New York to head the Houston hospital’s department of immunology.
Allison says this partnership will accelerate work that each institution is doing individually, enabling them to more quickly and efficiently investigate what sort of reactions cancer patients could have to therapies and which combination of treatments are best. “We hope to gain a more detailed understanding so we could help them more rapidly develop these drugs to get them to patients in a more timely manner,” he adds.
The three-year agreement with Pfizer is designed to accelerate the delivery of immune-based treatments to cancer patients, the development of new combination therapies, and the identification of useful biomarkers for guiding and monitoring treatment. Pfizer has invested an undisclosed amount in the project. Ferran Prat, MD Anderson’s vice president of strategic industry ventures, says that the investment will enable MD Anderson to spur development of drugs under investigation in Pfizer’s Rinat biotech unit, but he declined to provide details about the financial or licensing arrangements with Pfizer.
“The biggest advantage of this partnership is that everything is provided for in the beginning,” such as regulatory and budgetary approvals, he says. “We can be extremely agile in going from project to project,” he added. “It allows for much faster development.”
Prat added that the hospital is speaking to other pharmaceutical companies to forge similar agreements, with a second announcement possible today.
Ronald DePinho, the hospital’s president and CEO, unveiled the Moon Shots program a year after his 2011 arrival in Houston. I spoke with DePinho, an Xconomist, in November about the program, the hospital’s goals, and Allison’s work, which he said had yielded “the most exciting advances in medicine in the last 60 years.”
The Moon Shots program is an effort to dramatically reduce cancer deaths through six ambitious projects that target eight cancers—acute myeloid leukemia, myelodysplastic syndrome, chronic lymphocytic leukemia, melanoma, lung cancer, prostate cancer, so-called triple-negative breast cancer, and ovarian cancer. MD Anderson says it has invested $40 million to help fund moon shots efforts, including a $10-million grant from the Cancer Prevention and Research Institute of Texas, which helped bring Allison to Texas.
Allison brought with him his research on ipilimumab, a drug that takes the brakes off of immune T cells and frees them to combat cancer. In 2011 the drug, now marketed by Bristol-Myers Squibb as Yervoy, became the first-ever approved for late-stage melanoma, MD Anderson says.
Since that milestone, the hospital says that other so-called immune checkpoint blockades have been discovered and are advancing in clinical trials. MD Anderson is running clinical trials of ipilimumab and other agents that target melanoma, lymphoma, lung, breast, gastric, and prostate cancers, the hospital says.
For Jacqueline Northcut, president and CEO of BioHouston, the partnership plugs a gap in life sciences commercialization in Texas. “We can’t get drugs to market without industry partners, which Houston and Texas are sorely lacking,” she says. “So this is a home run for MD Anderson, Houston, and most importantly, cancer patients.”
Sorry, I didn't really answer your question, but just picked at the article.
I'm not really sure what weight Aethlon's patent holds. I would assume based on my reading that they hold the patent for any removal of exosomes from a person. If the patent doesn't do that, then why have a patent? Maybe someone else can give us a good explanation.
That's why I posted this. It's interesting that this article sort of gives MD Anderson credit for something that has been known for awhile. Not so much pancreatic cancer, but other known cancers relating to exosomes.
I like these statement within the article,
"This appears possible following the discovery that tiny particles the size of viruses called 'exosomes,' which are shed by cancer cells into the blood, contain the entire genetic blueprint of cancer cells."
Ending the paragraph
"The findings are based on research led by Raghu Kalluri, M.D., Ph.D., chairman and professor in MD Anderson's Department of Cancer Biology. The research results appear in the current online edition of the Journal of Biological Chemistry."
"This seminal discovery paves the way for highly sensitive screening for driver mutations of cancer in the blood without the need for biopsy of tumor tissue and importantly, lays the foundation for a new method for the early detection of cancer when the chance for cure is greatest," said MD Anderson President Ronald A. DePinho, M.D."
Just one MD Anderson discovery? There have been many exosome discovery before this...Why does this pave the way? What's not really fair is placing this type of broad information with a large name "MD Anderson" makes any normal reader think they discovered it. The writer should have went into a lot more detail..IMO
http://www.eurekalert.org/pub_releases/2014-01/uotm-rsa010814.php
Research suggests a blood test to locate gene defects associated with cancer may not be far off
HOUSTON, TX - Some surprising research findings from scientists at The University of Texas MD Anderson Cancer Center suggest it's possible a simple blood test could be developed to determine whether gene mutations associated with pancreatic cancer exist without the need of locating and testing tumor tissue. This appears possible following the discovery that tiny particles the size of viruses called 'exosomes,' which are shed by cancer cells into the blood, contain the entire genetic blueprint of cancer cells. By decoding this genomic data and looking for deletions and mutations associated with cancer, the research team believes this discovery could be translated into a test that helps physicians detect cancer and treat patients. The findings are based on research led by Raghu Kalluri, M.D., Ph.D., chairman and professor in MD Anderson's Department of Cancer Biology. The research results appear in the current online edition of the Journal of Biological Chemistry.
"At the present time, there is no single blood test that can screen for all cancer related DNA defects," said Kalluri. "In many cases, current protocols require a tumor sample to determine whether gene mutations and deletions exist and therefore determine whether the tumor itself is cancerous or benign. To procure tumor tissue, one needs to know that a tumor exists and if so, is it accessible for sample collection or removal? Finally, there are always risks and significant costs associated with surgical procedures to acquire tumor tissue."
Historically, researchers were aware these miniscule particles existed and that they carried nucleic acids and proteins. It was also believed that exosomes carried small portions of the person's DNA. However, upon further investigation, the MD Anderson research team was surprised to learn that the person's entire double-stranded genomic DNA spanning all chromosomes can be found in exosomes, including those mutated chromosomes that cause various cancers. Furthermore, Kalluri and colleagues discovered that DNA derived from exosomes carried the same cancer-related genetic mutations compared to the cancer cells taken from tumor.
"Because different forms of cancer are associated with different chromosomal mutations , we believe analysis of exosome DNA taken from blood samples may not only help determine the presence of a cancerous tumor somewhere in the body but also identify mutations without a need for tumor sample," added Kalluri. "We also believe this "fingerprint" will help lead us to the likely site of the tumor in the body. For instance, certain mutation spectrums would suggest pancreatic cancer or a brain-based tumor. While there is much more work to be conducted to develop such a test, having a tool such as this would increase our abilities to detect cancer in an earlier stage and therefore increase our chances of effective treatment."
"This seminal discovery paves the way for highly sensitive screening for driver mutations of cancer in the blood without the need for biopsy of tumor tissue and importantly, lays the foundation for a new method for the early detection of cancer when the chance for cure is greatest," said MD Anderson President Ronald A. DePinho, M.D.
###
The National Institutes of Health, Cancer Prevention and Research Institute of Texas and MD Anderson all provided funding to support this research.
I was thinking the same thing. Averaged down from .34 to .19. What's nice is this is the year Aethlon is placed on the biotech map. Anyone coming in now has it made compared to most of us that have been around 5+ years. I will say that watching Aethlon's movement and being apart of it during their struggles makes my investment worth it. It's weird that most people still have no idea what an exosome is, or what the Hemopurifier can do. I have a feeling this is the year that changes that. I'm a true believer and have always said that Aethlon will be the next Google of biotech. IMO. Just with the DARPA project could save thousands of lives. Add exosomes and Hep C and it's a no brainer....I just like being in the green for once :)
Some of you may not have read this article. It also mentions Aethlon and ESI.
http://zon.trilinkbiotech.com/2013/09/23/exosomes-tiny-packets-rnas-major-significance-potential/
Link requires a password
Looks to me that Aethlon is getting closer to that 2 mil mark. Now they just need 1358000. May be wrong, but that's how I understood it.
Just a quick note on the websites. Aethlon website is now at least 5 months outdated, maybe more. I'm not sure how long it takes, but they need to update soon. IMO they should not have had the grand opening for ESI without simultaneously producing a nice website to go with it. Grand opening is great, but now there's no website to show it exists within the internet world. Most common people automatically check the internet for websites.
It's obvious there will be a new site (Look)for Aethlon because no one is updating anything, except for the news, which I believe is automatically uploaded to the site. Another issue is why have a Facebook page if there are no updates there either. A professional, well maintained website is a necessity for good business. again IMO.
Need a laugh. I was telling my wife about everything going on with Aethlon and ESI. I brought up the majority owner of ESI and my wife laughed with a grin and said, "Sorry honey, I made an unauthorized purchase."
I'm surprised there is not a lot of talk regarding the grand opening party last night. Did anyone go? It would be nice to hear a little bit of what happened and who was there.
Also, I tried but could not watch or hear JJ's broadcast yesterday. Anyone have any news on that?